Skip to main content
RXST
NASDAQ Industrial Applications And Services

RxSight Issues Lower 2026 Revenue & Margin Guidance Following Mixed 2025 Results

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$8.81
Mkt Cap
$362.238M
52W Low
$6.32
52W High
$29.69
52W Position info
39% above low
Off High info
70% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

RXST sits 39% above its 52-week low of $6.32.

Summary

RxSight reported a 4% revenue decrease and widened net loss for full-year 2025, while providing 2026 guidance that projects lower revenue and gross margins, signaling a challenging outlook.


Key Events · Earnings and Guidance · RXST

  • Issues Lower 2026 Financial Guidance

    The company projects full-year 2026 revenue between $120.0 million and $135.0 million, a potential decrease from 2025's $134.5 million. Gross margin is guided to be 70% to 72%, down from 76.6% in 2025, primarily due to lower Light Delivery Device (LDD) production volumes.

  • Reports Mixed Full-Year 2025 Results

    Global sales for 2025 decreased 4% year-over-year to $134.5 million, with a 12% increase in Light Adjustable Lens (LAL) unit sales offset by a 48% decrease in LDD system sales. Net loss widened significantly to $(38.9) million, or $(0.95) per share, compared to $(27.5) million in 2024.

  • Q4 2025 Revenue Declined

    Total revenue for the fourth quarter of 2025 was $32.6 million, a 19% decrease compared to $40.2 million in Q4 2024, largely reflecting a 72% decline in LDD revenue. Net loss for the quarter was $(9.2) million, or $(0.22) per share.


Analysis · RXST · Industrial Applications And Services

RxSight, Inc. reported a mixed financial performance for full-year 2025, with overall revenue decreasing by 4% year-over-year to $134.5 million, despite a 12% growth in Light Adjustable Lens (LAL) unit sales. However, the company's net loss significantly widened to $(38.9) million from $(27.5) million in 2024. The most impactful aspect of this filing is the company's 2026 financial guidance, which projects revenue of $120.0 to $135.0 million, representing a potential decrease from 2025's actuals, and a lower gross margin of 70% to 72% compared to 76.6% in 2025. This downward revision in future outlook for both top-line growth and profitability signals a challenging period ahead. This guidance follows closely after the company filed a post-effective amendment to its S-3 registration statement on February 13, 2026, for a potential $200 million offering, indicating a need for capital that is now underscored by a weaker financial outlook.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, RXST was trading at $8.81 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $362.2M. The 52-week trading range was $6.32 to $29.69. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

RXST - Latest Insights

RXST
Nov 03, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.92
Real-time Price: $4.54 info
Change: +$0.620 (+16%) info
Market Cap: $190.359M info
RXST
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.59
Real-time Price: $4.54 info
Change: -$0.050 (-1%) info
Market Cap: $190.359M info
RXST
Nov 03, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $4.59
Real-time Price: $4.54 info
Change: -$0.050 (-1%) info
Market Cap: $190.359M info
RXST
Aug 10, 2026, 8:01 AM EDT
Filing Type: SC TO-I
Importance Score:
7
Price at Filing: $6.26
Real-time Price: $4.54 info
Change: -$1.72 (-27%) info
Market Cap: $190.359M info
RXST
Jul 15, 2026, 4:23 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $5.25
Real-time Price: $4.54 info
Change: -$0.710 (-14%) info
Market Cap: $190.359M info